Meeting
2022 ASCO Annual Meeting
Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.
Authors
Mehrdad Rakaee
UiT The Arctic University of Norway, Tromsø, Norway
Mehrdad Rakaee , Elio Adib , Biagio Ricciuti , Lynette M. Sholl , Weiwei Shi , Joao Victor Machado Alessi , Alessio Cortellini , Claudia A.M. Fulgenzi , David J. James Pinato , Sayed MS Hashemi , Idris Bahce , Ilias Houda , Simin Jamaly , Sigve Andersen , Tom Donnem , Mark M. Awad , David J. Kwiatkowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9065)
DOI
10.1200/JCO.2022.40.16_suppl.9065
Abstract #
9065
Poster Bd #
53
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
Poster
2022 ASCO Annual Meeting
A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).
First Author: Wafik S. El-Deiry
Poster
2020 ASCO Virtual Scientific Program
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
First Author: Deborah Blythe Doroshow
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
First Author: Eric Nadler